ProductUpdated on 19 November 2025
Factor B and protein C2 point mutants, a method of enhancing the activity of anti-cancer antibodies, the pharmaceutical composition and the use of mutants
Innovation Broker | Project Coordinator at Medical University of Gdańsk - Technology Transfer Office
Gdańsk, Poland
About
The subject of the offer is an invention allowing us to enhance the cytotoxic activity of antibody-based drugs used, among others, to fight haematological malignancies. A patent was awarded to this invention in Poland, bearing number Pat.237868 and in the United States with the number USAppl.np.17/045058.
Similar opportunities
Investment
- Startup
- Seed and Development
- BIOLOGY / BIOTECHNOLOGY
- INTELLECTUAL PROPERTY, LEGAL AND FINANCIAL SERVICES
Rodrigo de Pablos
CEO at Bioreplica
Las Palmas, Spain
Product
- MEDICINE
- LIFE SCIENCE
- THERAPEUTIC AREA
- Re-Seller/Wholesaler
- BIOLOGY / BIOTECHNOLOGY
Vanessa Vankerckhoven
CEO | Founder at Idevax
Antwerp, Belgium
Product
Synthesis of lipopeptide conjugates in the treatment of chronic wounds
Marcin Stolarek
Innovation Broker | Project Coordinator at Medical University of Gdańsk - Technology Transfer Office
Gdańsk, Poland